REPLIGEN CORP
No enriched coverage for $RGEN in the last 7 days.
BioLife Solutions (NASDAQ: BLFS) said it plans a cash-stock merger with Repligen, according to the company. The deal terms and timing were not provided in the excerpt, but it would combine the businesses under a merger agreement.
Simply Wall St reports Repligen (RGEN) rose 6.9% after Q2 2026 results. Revenue increased to $204.13M from $182.37M, but net income fell to $5.01M from $14.87M and diluted EPS declined to $0.09 from $0.26. Analysts reportedly raised earnings estimates despite margin pressure and noted Russell index removals.
Repligen (NASDAQ:RGEN) reported Q2 growth in chromatography revenue in the low double digits, driven by OPUS columns and demand from CDMOs and biopharma. Filtration revenue rose slightly, with headwinds tied to gene therapy issues, ATF customer inventory, site readiness delays, and the Polymem divestiture. Repligen raised 2026 revenue outlook to $813M-$834M and EPS to $2.03-$2.09, excluding BioLife acquisition.
Recent RGEN coverage spans earnings, mergers & acquisitions and financial news.
In the last 30 days, RGEN insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($80K). The most active reporter was Garland Jason K, CFO, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
BioLife Solutions (NASDAQ: BLFS) said it plans a cash-stock merger with Repligen, according to the company. The deal terms and timing were not provided in the excerpt, but it would combine the businesses under a merger agreement.
Mixed Q2 results show revenue growth with margin compression, while analysts reportedly raised earnings estimates, supporting near-term upside but keeping profitability risk elevated.
Raised full-year guidance and provided acquisition-related synergy and EPS accretion expectations, offset by continued filtration headwinds into Q3.
Beat supports incremental positive sentiment.
PT increase and implied upside can support near-term sentiment, but it is not a new fundamental catalyst.
alphai scores every news story that mentions RGEN with an AI model for sentiment and relevance, and aggregates insider trades from REPLIGEN CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
BioLife Solutions (NASDAQ: BLFS) said it plans a cash-stock merger with Repligen, according to the company. The deal terms and timing were not provided in the excerpt, but it would combine the businesses under a merger agreement.
2 min readSimply Wall St reports Repligen (RGEN) rose 6.9% after Q2 2026 results. Revenue increased to $204.13M from $182.37M, but net income fell to $5.01M from $14.87M and diluted EPS declined to $0.09 from $0.26. Analysts reportedly raised earnings estimates despite margin pressure and noted Russell index removals.
4 min readRepligen (NASDAQ:RGEN) reported Q2 growth in chromatography revenue in the low double digits, driven by OPUS columns and demand from CDMOs and biopharma. Filtration revenue rose slightly, with headwinds tied to gene therapy issues, ATF customer inventory, site readiness delays, and the Polymem divestiture. Repligen raised 2026 revenue outlook to $813M-$834M and EPS to $2.03-$2.09, excluding BioLife acquisition.
7 min readMorgan Stanley research cited by the article says the median S&P 500 EPS surprise was 6% in Q1 2026, above the long-run ~5.5% average. FactSet research cited says firms with positive EPS surprises tend to keep outperforming after results. The article lists 28 companies that beat Wall Street EPS expectations, including Ford (EPS $0.66 vs $0.31), Bloom Energy (EPS $0.78 vs $0.37; revenue >$1B, +164% YoY), and Incyte (EPS $3.09 vs $0.94).
7 min readAnalyst estimates for Repligen (RGEN) show the average 12-month price target increased from $176.28 to $180.33, based on 18 analysts. Targets range from $145 to $220. Using the Jul. 27 close, the target implies about 38% upside. The consensus rating remains “Buy” with 19 Buys, 3 Holds, and 0 Sells.
1 min readRepligen (NASDAQ: RGEN) shares rose 14.6% after the company reported Q2 results that beat expectations and lifted its full-year outlook. Adjusted EPS was $0.54 vs $0.45 expected, and revenue was $204.1M, up 11.9% year over year. Full-year revenue guidance was raised to about $824M and adjusted EPS to $2.03 to $2.09.
3 min readRepligen (RGEN) reported Q2 2026 earnings call updates. CEO Olivier Loeillot said order trends strengthened into Q2 and supported raised full-year guidance for 10.5% to 13.5% organic growth (midpoint 12%). Protein revenue grew about 50% on portfolio strength, and equipment orders improved with a book-to-bill above 1, building backlog for 2027.
6 min readRepligen (NASDAQ: RGEN) shares rose about 13.77% after the company agreed to buy BioLife Solutions for about $1.5B in a cash-and-stock deal. Management said 64% of consideration is RGEN stock and 36% cash, with closing targeted for Q4 2026. The deal is expected to be accretive, with at least $0.05 adjusted EPS in year one and $0.25 in year two, plus $20M-$30M synergies over two years.
5 min readRepligen (RGEN) reported Q2 FY2026 revenue of $204M, up 12% reported and 13% organic. Adjusted EPS rose 46% to $0.54, with adjusted gross margin up 280 bps to 53.9% and operating margin up 460 bps to 16.7%. The company raised full-year guidance to $2.03-$2.09 adjusted EPS and expects 10.5%-13.5% organic growth, citing order momentum and Proteins/Analytics strength. It also agreed to acquire BioLife, expected to close in Q4 2026.
6 min readRepligen (NASDAQ: RGEN) shares rose about 15.9% after news of a BioLife Solutions acquisition valued around $1.5B, with BioLife priced at $31 per share. The deal is expected to be accretive, with management citing $20M to $30M cost synergies over two years and adjusted EPS increases of at least $0.05 in year one and $0.25 in year two.
4 min read
